Current Concepts of the Biology of Human Cutaneous Malignant Melanoma (Q39620194)

13 September 2017

1 reference

title

Current concepts of the biology of human cutaneous malignant melanoma (English)

1 reference

13 September 2017

Current Concepts of the Biology of Human Cutaneous Malignant Melanoma (English)

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

author name string

Clark WH Jr

1

1 reference

13 September 2017

W. H. Clark

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A322460

16 March 2023

M. J. Mastrangelo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A322460

16 March 2023

A. M. Ainsworth

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A322460

16 March 2023

D. Berd

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A322460

16 March 2023

R. E. Bellet

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A322460

16 March 2023

E. A. Bernardino

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A322460

16 March 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=322460

16 March 2023

publication date

1 January 1977

1 reference

Advances in Cancer Research

13 September 2017

published in

1 reference

13 September 2017

volume

24

1 reference

13 September 2017

page(s)

267-338

1 reference

Primary malignant melanoma of the urinary bladder

13 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

2

34

2077

Alexander

1974

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

A reorientation on the histogenesis and clinical significance of cutaneous nevi and melanomas

16 March 2023

3

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Malignant melanoma; a clinicopathological analysis of the criteria for diagnosis and prognosis

16 March 2023

4

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Ceinical characteristics of the genetic variety of cutaneous melanoma in man

16 March 2023

5

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

7

34

2066

Anderson

1974

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Malignant melanoma in siblings

16 March 2023

8

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Brief communication: tumor-associated fetal antigens in human tumors

16 March 2023

10

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Malignant melanoma: the patient with an unknown site of primary origin

16 March 2023

11

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Oncornavirus-like particles in human skin cancers

16 March 2023

12

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

In vitro assays of cell-mediated immunity to human solid tumors: problems of quantitation, specificity, and interpretation

16 March 2023

13

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Annals of the New York Academy of Sciences

16 March 2023

15

author name string

Bast

publication date

1976

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

16

35

2902

Bean

1975

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Sequentialin vitro reactivity of lymphocytes from melanoma patients receiving immunotherapy compared with the reactivity of lymphocytes from healthy donors

16 March 2023

19

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Virus-like particles in metastases of human malignant melanoma

16 March 2023

21

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Inhibition of leukocyte migration in agarose by KC1 extracts of a human melanoma cell line grown in serum-free medium

16 March 2023

23

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

24

35

189

Bodurtha

1975

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

A clinical histologic, and immunologic study of a case of metastatic malignant melanoma undergoing spontaneous remission

16 March 2023

25

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Skin transplantation immunity in relation to hypersensitivity

16 March 2023

26

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma

16 March 2023

27

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Tumor Thickness, Level of Invasion and Node Dissection in Stage I Cutaneous Melanoma

16 March 2023

28

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Long-term spontaneous regression of malignant melanoma with visceral metastasesReport of a case with immunologic profile

16 March 2023

29

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Humoral cytotoxicity in melanoma patients and its correlation with the extent and course of the disease

16 March 2023

32

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Evidence for a Tumour-associated Antigen in Human Malignant Melanoma

16 March 2023

33

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Abnormalities of quantitative dinitrochlorobenzene sensitization in cancer patients: correlation with tumor stage and histology

16 March 2023

34

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Genetic aspects of malignant melanoma

16 March 2023

35

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Patient survival after chemotherapy and its relationship to in vitro lymphocyte blastogenesis

16 March 2023

39

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

45

29

705

Clark

1969

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Cell-mediated immunity in malignant melanoma

16 March 2023

48

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Spontaneous regression of cancer: the metabolic triumph of the host?

16 March 2023

50

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Antibodies and antigen expression in human melanoma detected by the immune adherence test

16 March 2023

51

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Serum mediated inhibition of the immunological reactions of the patient to his own tumour: a possible role for circulating antigen

16 March 2023

52

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Immunization with Irradiated Tumour Cells and Specific Lymphocyte Cytotoxicity in Malignant Melanoma

16 March 2023

53

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Humoral and cell-mediated immune response in patients with malignant melanoma.I. In vitro lymphocyte reactivity to pha and antigens following immunization

16 March 2023

56

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Cytotoxic lymphocytes in melanoma patients

16 March 2023

57

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Cytotoxity of non-T versus T-lymphocytes from melanoma patients and healthy donors on short- and long-term cultured melanoma cells

16 March 2023

58

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

The influence of different isolation procedures and the use of target cells from melanoma cell lines and short-term cultures on the non-specific cytotoxic effects of lymphocytes from healthy donors

16 March 2023

59

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Impaired immunologic reactivity and recurrence following cancer surgery

16 March 2023

61

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Adjuvant Immunotherapy with BCG in Treatment of Regional-Lymph-Node Metastases from Malignant Melanoma

16 March 2023

62

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

The specificity of the cytoplasmic antigen in human malignant melanoma.

16 March 2023

63

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Relationship of melanoma and other skin cancer mortality to latitude and ultraviolet radiation in the United States and Canada.

16 March 2023

66

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Macrophages in syngeneic animal tumours

16 March 2023

67

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Cell-mediated immunity to human tumors. Abrogation by serum factors and nonspecific effects of oral BCG therapy

16 March 2023

69

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Cutaneous hypersensitivity reactions to autologous extracts of malignant melanoma cells

16 March 2023

70

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Cellular and humoral immunity against human malignant melanoma

16 March 2023

72

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

73

14

327

Foulds

1954

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

74

25

1339

Foulds

1965

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Malignant melanoma and coexisting malignant neoplasms

16 March 2023

76

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

78

36

458

Fritze

1976

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

In vitro cell migration as a model for delayed hypersensitivity

16 March 2023

80

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Active specific immunization in malignant melanoma

16 March 2023

81

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

82

34

1833

Golub

1974

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Epstein-Barr virus binding sites on lymphocyte subpopulations and the origin of lymphoblasts in cultured lymphoid cell lines and in the blood of patients with infectious mononucleosis

16 March 2023

83

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

INCIDENCE OF MALIGNANCY IN GIANT PIGMENTED NEVI

16 March 2023

84

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Active immunotherapy with B.C.G. for recurrent malignant melanoma

16 March 2023

86

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Chemoimmunotherapy of Disseminated Malignant Melanoma with Dimethyl Triazeno Imidazole Carboxamide and Bacillus Calmette-Guérin

16 March 2023

87

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Tumor thickness and lymphocytic infiltration in malignant melanoma of the head and neck

16 March 2023

89

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Presence and possible role of anti-IgG antibodies in human malignancy.

16 March 2023

90

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Further studies on the ability of regressor sera to block cell-mediated destruction of Rous sarcomas

16 March 2023

91

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Demonstration of cell-mediated immunity to human neoplasms of various histological types

16 March 2023

93

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Blocking of cell‐mediated tumor immunity by sera from patients with growing neoplasms

16 March 2023

94

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Serum factors in tumor-free patients cancelling the blocking of cell-mediated tumor immunity.

16 March 2023

95

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Destruction of cultivated melanoma cells by lymphocytes from healthy black (North American Negro) donors

16 March 2023

96

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Sequential studies on cell-mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma

16 March 2023

97

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Increase of lymphocyte-mediated tumor-cell destruction by certain patient sera

16 March 2023

98

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Observations on childhood infections with the Epstein-Barr virus

16 March 2023

99

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Cell-mediated and serum blocking reactivity to tumor antigens in patients with malignant melanoma

16 March 2023

102

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Problems Associated With Study of Cell-Mediated Immunity to Human Tumors by Microcytotoxicity Assays

16 March 2023

103

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Analysis of soluble melanoma cell membrane antigens in metastatic cells of various organs and further studies of antigens present in primary melanoma

16 March 2023

106

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Soluble membrane antigens of human malignant melanoma cells.

16 March 2023

107

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells.

16 March 2023

114

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Cytogenetic studies on human lymphoblastoid cell lines from Burkitt's lymphomas and other sources

16 March 2023

115

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

In vitro lymphocyte stimulation by a soluble antigen from malignant melanoma

16 March 2023

116

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

The risk of malignancy in large congenital nevi

16 March 2023

117

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

118

17

174

Ketcham

1975

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

The Epstein-Barr Virus and Neoplasia

16 March 2023

119

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Archiv für Geschwulstforschung

16 March 2023

122

37

368

Klug

1971

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Ultrastructural differences in human malignant melanomata. An electron microscopical study

16 March 2023

125

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

The genetics of childhood cancer

16 March 2023

126

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

The trend of mortality from primary malignant tumors of skin

16 March 2023

130

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

A multiphase immunotherapy regimen for human melanoma: clinical and laboratory results.

16 March 2023

135

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Possible immunological factors in human malignant melanoma in Uganda

16 March 2023

136

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

The specificity of surface membrane immunofluorescence in human malignant melanoma.

16 March 2023

137

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Tumour-specific Antibodies in Human Malignant Melanoma and their Relationship to the Extent of the Disease

16 March 2023

138

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Possible Explanation for Loss of Detectable Antibody in Patients with Disseminated Malignant Melanoma

16 March 2023

139

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

The significance of humoral antibodies in the localization of human malignant melanoma

16 March 2023

141

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Annals of the New York Academy of Sciences

16 March 2023

142

author name string

Lewis

publication date

1976

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma

16 March 2023

143

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies

16 March 2023

144

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy

16 March 2023

145

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Inhibition of leukocyte migration by tumor-associated antigens in soluble extracts of human malignant melanoma

16 March 2023

148

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

The classification of melanoma and its relationship with prognosis

16 March 2023

149

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

The classification of malignant melanoma and its histologic reporting

16 March 2023

150

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Cell-mediated immunity in patients with malignant melanoma

16 March 2023

151

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Incidence of malignant melanoma of the skin in Norway, 1955-1970. Variations in time and space and solar radiation

16 March 2023

152

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Tumor immunology with particular reference to malignant melanoma

16 March 2023

153

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Marker band in one chromosome 14 from Burkitt lymphomas.

16 March 2023

154

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Congenital melanocytic nevi of the small and garment type. Clinical, histologic, and ultrastructural studies

16 March 2023

155

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Intralesional BCG in the treatment of metastatic malignant melanoma

16 March 2023

156

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Spontaneous regression of malignant melanoma. Pathologic and immunologic study in a ten year survivor

16 March 2023

159

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Tumor-Directed Immune Reactivity and Immunotherapy in Malignant Melanoma. Current Status1

16 March 2023

163

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Lymphocyte blastogenesis induced by autochthonous human solid tumor cells: Relationship to stage of disease and serum factors

16 March 2023

164

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Brief communication: melanoma-specific antibodies produced in monkeys by immunization with human melanoma cell lines.

16 March 2023

165

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

The familial aspect of malignant melanoma

16 March 2023

166

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Melanosis circumscripta praecancerosa (Dubreuilh), a non-nevoid premelanoma distinct from junction nevus

16 March 2023

167

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Melanocytic and nevocytic malignant melanomas.Cellular and subcellular differentiation

16 March 2023

170

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

A report of malignant melanoma of the skin in sisters

16 March 2023

175

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

176

35

3721

Mukherji

1975

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Selective and non-selective lymphocytotoxicity in human melanoma: Observation on the effect of long-term culture and fetal bovine serum on target-cell sensitivity to lymphocytes

16 March 2023

177

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Use of formalin‐fixed melanoma cells for the detection of antibodies against surface antigens by a micro‐immune adherence technique

16 March 2023

178

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Primary melanoma of the esophagus

16 March 2023

179

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

180

30

1828

Nagel

1970

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Evidence for tumor-specific immunity in human malignant melanoma

16 March 2023

181

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis

16 March 2023

183

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Development and elimination of pigmented moles, and the anatomical distribution of primary malignant melanoma

16 March 2023

184

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Prevalence, incidence and persistence of EB virus antibody in young adults

16 March 2023

185

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

DNA of Epstein-Barr virus detected in tissue of Burkitt's lymphoma and nasopharyngeal carcinoma

16 March 2023

186

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

188

32

2845

Oettgen

1972

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Cellular Microcytotoxicity in Human Tumor Systems: Analysis of Results2

16 March 2023

189

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

IgA as a blocking factor in human malignant melanoma

16 March 2023

190

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

End results in the treatment of malignant melanoma; a report of 1190 cases

16 March 2023

193

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Detection in human melanoma cell lines of particles with some properties in common with RNA tumour viruses

16 March 2023

195

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

200

35

2729

Pierce

1975

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Specific responsiveness of leukocytes to soluble extracts of human tumors

16 March 2023

202

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

GIANT PIGMENTED NEVI, MELANOMA, AND LEPTOMENINGEAL MELANOCYTOSIS: A CLINICAL AND HISTOPATHOLOGICAL STUDY

16 March 2023

203

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Tumour-specific antibody neutralization of factors in rat hepatoma-bearer serum which abrogate lymph-node-cell cytotoxicity.

16 March 2023

204

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Human Malignant Melanoma Antibodies Demonstrated by Immunofluorescence

16 March 2023

208

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Isolation of a soluble tumor-associated antigen from human melanoma

16 March 2023

212

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

Giant pigmented nevi

213

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Melanoma in twins.Cutaneous malignant melanoma in identical twins from a set of triplets

16 March 2023

214

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

FAMILIAL MALIGNANT MELANOMA. A PEDIGREE AND CYTOGENETIC STUDY

16 March 2023

215

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

In vitro study of cellular immunity against autochthonous human cancer

16 March 2023

216

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

Familial Melanoma

219

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Spontaneous regression of primary malignant melanomas with regional metastases

16 March 2023

220

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Combined immunotherapy in malignant melanoma. Regression of metastatic lesions in two patients concordant in timing with systemic administration of transfer factor and Bacillus Calmette-Guérin

16 March 2023

222

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Report of a workshop on the immune response to solid tumours in man

16 March 2023

223

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

The presence of delayed hypersensitivity reactions in patients toward cellular extracts of their malignant tumors. 1. The role of tissue antigen, nonspecific reactions of nuclear material, and bacterial antigen as a cause for this phenomenon

16 March 2023

224

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Spontaneous regression of human melanoma: clinical and experimental studies

16 March 2023

225

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

The Regional Anatomy of the Human Integument with Special Reference to the Distribution of Hair Follicles, Sweat Glands and Melanocytes

16 March 2023

226

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

227

33

2898

Takasugi

1973

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

FAMILIAL FACTOR IN MALIGNANT MELANOMA

16 March 2023

231

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

The influence of tumour burden and therapy on cellular cytotoxicity responses in patients with ocular and skin melanoma

16 March 2023

232

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Lymphocyte toxicity test in clinical melanoma

16 March 2023

234

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Identification of an antigen associated with malignant melanoma

16 March 2023

236

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Genetic factor in malignant melanoma

16 March 2023

237

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Familial Malignant Melanoma

16 March 2023

238

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Malignant melanoma of the extremities: A clinicopathologic study using levels of invasion (microstage)

16 March 2023

239

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Fluorescent antibody studies in malignant melanoma.

16 March 2023

241

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Immunofluorescent Studies of the Serologic Reactivity of Patients With Malignant Melanoma Against Tumor-Associated Cytoplasmic Antigens23

16 March 2023

243

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas

16 March 2023

244

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Immunologic studies in patients with malignant melanoma in Uganda

16 March 2023

246

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

Epstein–Barr Virus in Burkitt's Lymphoma and Nasopharyngeal Carcinoma: EBV DNA in Biopsies of Burkitt Tumours and Anaplastic Carcinomas of the Nasopharynx

16 March 2023

247

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)61017-9

16 March 2023

Identifiers

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=322460

16 March 2023

1 reference